SGStephanie Geisler

Stephanie Geisler

*This is an algorithmically generated author record based on publicly available information.

Stephanie Geisler has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patterns and drivers of uncovered outdoor run use in group-housed sows after weaning

    by Swantje Geisler, Karen Pabst, Mario Hasler, Astrid.L. van Asten, Nicole Kemper, Imke Traulsen

  • Open Access

    Animal performance and meat quality of two slow-growing chicken genotypes fed insects reared on municipal organic waste

    by B.A. Altmann, S. Geisler, F. Morthorst, S. Angeli, S. Bortolini, M. Gauly, J. Hummel, A. Sünder, D. Mörlein, I. Traulsen, et al.

    To keep up with increasing demand for animal protein, alternative protein sources will need to be included in current animal production systems. The efficient growth of Hermetia illucens larvae combined with municipal waste as a substrate has the potential to increase the sustainability of protein feed production. Therefore, this study partially substituted soymeal with H. illucens larval meal (reared on municipal waste) in broiler diets to determine the effect on slow-growing broiler (ISA-JA-757 and Les Bleues) production. Growth and slaughter performance, as well as animal welfare and meat quality parameters were evaluated. No influence of H. illucens larvae meal in the diet was found for weight gain, feed efficiency and slaughter performance. Animal welfare was also not influenced by diet. Fatty acid composition of intramuscular fat was influenced by the inclusion of H. illucens in the broiler diets; however not uniformly across meat cut. Differences between animal genotype and animal sex often influenced parameters under investigation more than diet itself. Overall, H. illucens can be regarded as a suitable protein source in slow-growing broiler diets.


  • Open Access

    Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo

    by Stian Knappskog, Elisabet O. Berge, Ranjan Chrisanthar, Stephanie Geisler, Vidar Staalesen, Beryl Leirvaag, Synnøve Yndestad, Elise de Faveri, Bård O. Karlsen, David C. Wedge, et al.

    Chemoresistance is the main obstacle to cancer cure. Contrasting studies focusing on single gene mutations, we hypothesize chemoresistance to be due to inactivation of key pathways affecting cellular mechanisms such as apoptosis, senescence, or DNA repair. In support of this hypothesis, we have previously shown inactivation of either TP53 or its key activators CHK2 and ATM to predict resistance to DNA damaging drugs in breast cancer better than TP53 mutations alone. Further, we hypothesized that redundant pathway(s) may compensate for loss of p53‐pathway signaling and that these are inactivated as well in resistant tumour cells. Here, we assessed genetic alterations of the retinoblastoma gene (RB1) and its key regulators: Cyclin D and E as well as their inhibitors p16 and p27. In an exploratory cohort of 69 patients selected from two prospective studies treated with either doxorubicin monotherapy or 5‐FU and mitomycin for locally advanced breast cancers, we found defects in the pRB‐pathway to be associated with therapy resistance (p‐values ranging from 0.001 to 0.094, depending on the cut‐off value applied to p27 expression levels). Although statistically weaker, we observed confirmatory associations in a validation cohort from another prospective study (n = 107 patients treated with neoadjuvant epirubicin monotherapy; p‐values ranging from 7.0 × 10−4 to 0.001 in the combined data sets). Importantly, inactivation of the p53‐and the pRB‐pathways in concert predicted resistance to therapy more strongly than each of the two pathways assessed individually (exploratory cohort: p‐values ranging from 3.9 × 10−6 to 7.5 × 10−3 depending on cut‐off values applied to ATM and p27 mRNA expression levels). Again, similar findings were confirmed in the validation cohort, with p‐values ranging from 6.0 × 10−7 to 6.5 × 10−5 in the combined data sets. Our findings strongly indicate that concomitant inactivation of the p53‐ and pRB‐ pathways predict resistance towards anthracyclines and mitomycin in breast cancer in vivo.